The 50-day moving average for ALEC moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +7.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALEC as a result. In 88 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for ALEC turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
ALEC moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALEC crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ALEC entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.495) is normal, around the industry mean (3.037). P/E Ratio (-1.679) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BCYC advanced for three days, in 188 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BCYC's RSI Oscillator exited the oversold zone, 34 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 69 cases where BCYC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for BCYC just turned positive on October 22, 2026. Looking at past instances where BCYC's MACD turned positive, the stock continued to rise in 31 of 47 cases over the following month. The odds of a continued upward trend are 66%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCYC as a result. In 71 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
BCYC moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
BCYC broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BCYC entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.501) is normal, around the industry mean (3.037). P/E Ratio (-1.337) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ALEC | BCYC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 52 | 74 | |
P/E GROWTH RATING 1..100 | 75 | 25 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALEC's Valuation (8) in the Biotechnology industry is in the same range as BCYC (37) in the null industry. This means that ALEC’s stock grew similarly to BCYC’s over the last 12 months.
ALEC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that ALEC’s stock grew similarly to BCYC’s over the last 12 months.
BCYC's SMR Rating (97) in the null industry is in the same range as ALEC (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to ALEC’s over the last 12 months.
ALEC's Price Growth Rating (52) in the Biotechnology industry is in the same range as BCYC (74) in the null industry. This means that ALEC’s stock grew similarly to BCYC’s over the last 12 months.
BCYC's P/E Growth Rating (25) in the null industry is somewhat better than the same rating for ALEC (75) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than ALEC’s over the last 12 months.
| ALEC | BCYC | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 66% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 73% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 87% |
| Advances ODDS (%) | 8 days ago 84% | 8 days ago 76% |
| Declines ODDS (%) | 6 days ago 86% | 14 days ago 89% |
| BollingerBands ODDS (%) | N/A | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALEC’s FA Score shows that 1 FA rating(s) are green while BCYC’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALEC’s TA Score shows that 3 TA indicator(s) are bullish while BCYC’s TA Score has 4 bullish TA indicator(s).
ALEC (@Biotechnology) experienced а -6.15% price change this week, while BCYC (@Biotechnology) price change was +3.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.65%. For the same industry, the average monthly price growth was -11.32%, and the average quarterly price growth was -14.09%.
ALEC is expected to report earnings on Nov 05, 2026.
BCYC is expected to report earnings on Oct 29, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MLDR | 47.31 | 0.81 | +1.75% |
| Global X Intermediate-Term Treasury Ladder ETF (MLDR) | |||
| PTF | 107.23 | 1.52 | +1.43% |
| Invesco Dorsey Wright Technology Momentum ETF (PTF) | |||
| SLYG | 108.38 | 0.79 | +0.73% |
| State Street SPDR S&P 600 Small Cap Growth ETF (SLYG) | |||
| DDFO | 23.04 | 0.07 | +0.30% |
| Innovator Equity Dual Directional 15 Buffer ETF - October (DDFO) | |||
| EZET | 17.53 | -0.57 | -3.15% |
| Franklin Ethereum ETF (EZET) | |||